184 related articles for article (PubMed ID: 8683038)
1. Pretreatment of human peripheral blood lymphocytes with interleukin-2 or dexamethasone does not alter their response to Met-Enkephalin in a NK-cytotoxic assay.
Martin-Kleiner I; Gabrilovac J
Immunopharmacol Immunotoxicol; 1996 Feb; 18(1):37-57. PubMed ID: 8683038
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism.
Rook AH; Hooks JJ; Quinnan GV; Lane HC; Manischewitz JF; Macher AM; Masur H; Fauci AS; Djeu JY
J Immunol; 1985 Mar; 134(3):1503-7. PubMed ID: 3918102
[TBL] [Abstract][Full Text] [Related]
3. Naloxone modulates NK-cell activity of human peripheral blood lymphocytes like an opioid agonist.
Martin-Kleiner I; Gabrilovac J
Immunopharmacol Immunotoxicol; 1993; 15(2-3):179-97. PubMed ID: 7688780
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory effects of corticosteroids on natural killer and antibody-dependent cellular cytotoxic activities of human lymphocytes.
Nair MP; Schwartz SA
J Immunol; 1984 Jun; 132(6):2876-82. PubMed ID: 6202765
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human natural killer cell activity by the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine is an early but post-binding event.
Steele TA; Brahmi Z
J Immunol; 1988 Nov; 141(9):3164-9. PubMed ID: 3262683
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
[TBL] [Abstract][Full Text] [Related]
7. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
8. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
9. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum.
Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z
Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757
[TBL] [Abstract][Full Text] [Related]
10. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12.
Cesano A; Visonneau S; Clark SC; Santoli D
J Immunol; 1993 Sep; 151(6):2943-57. PubMed ID: 8104216
[TBL] [Abstract][Full Text] [Related]
11. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
12. Depletion of NK cells with the lysosomotropic agent L-leucine methyl ester and the in vitro generation of NK activity from NK precursor cells.
Shau H; Golub SH
J Immunol; 1985 Feb; 134(2):1136-41. PubMed ID: 3871208
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
Naume B; Gately M; Espevik T
J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
[TBL] [Abstract][Full Text] [Related]
14. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
15. Interplay in vitro between ACTH, beta-endorphin, and glucocorticoids in the modulation of spontaneous and lymphokine-inducible human natural killer (NK) cell activity.
Gatti G; Masera RG; Pallavicini L; Sartori ML; Staurenghi A; Orlandi F; Angeli A
Brain Behav Immun; 1993 Mar; 7(1):16-28. PubMed ID: 8386029
[TBL] [Abstract][Full Text] [Related]
16. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
17. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH
Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity.
Gan X; Zhang L; Solomon GF; Bonavida B
Brain Behav Immun; 2002 Jun; 16(3):227-46. PubMed ID: 12009684
[TBL] [Abstract][Full Text] [Related]
19. Effect of human alpha-fetoprotein on native and in vitro-stimulated NK activity.
Cardoso E; Valdez G; Comini E; Matera L
J Clin Lab Immunol; 1991 Apr; 34(4):183-8. PubMed ID: 1726567
[TBL] [Abstract][Full Text] [Related]
20. Effect of interleukin-2 on the monomeric IgG-induced inhibition of human natural killer cell activity.
Gherman M; Herberman RB; Sulica A
Nat Immun Cell Growth Regul; 1989; 8(5):255-65. PubMed ID: 2512481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
